Aclaris Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACRS Nasdaq 2834 www.aclaristx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - May 8th, 2026 6:30 am
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - May 7th, 2026 6:50 am
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - May 7th, 2026 4:59 am
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates - May 5th, 2026 4:05 pm
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth - May 4th, 2026 4:04 am
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus - Apr 28th, 2026 8:17 am
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor - Apr 28th, 2026 4:30 am
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 - Apr 27th, 2026 2:45 pm
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming - Apr 14th, 2026 4:04 pm
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Apr 8th, 2026 6:30 am
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 - Mar 27th, 2026 8:10 am
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains? - Mar 26th, 2026 7:25 am
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Mar 20th, 2026 9:00 am
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - Mar 18th, 2026 4:55 am
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference - Mar 10th, 2026 12:51 pm
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference - Mar 3rd, 2026 5:00 am
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference - Feb 26th, 2026 8:59 am
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates - Feb 26th, 2026 7:45 am
Aclaris: Q4 Earnings Snapshot - Feb 26th, 2026 5:09 am
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Feb 26th, 2026 4:58 am